Beximco Pharmaceuticals (LSE:BXP) Total Premiums Earned

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LSE:BXP Beximco Pharmaceuticals PLC LSE:BXP
55 GF Score
Price £0.63
GF Value £0.49
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Beximco Pharmaceuticals Total Premiums Earned?

Total Premiums Earned only applies to insurance companies.

LSE:BXP
55GF Score
Beximco Pharmaceuticals PLC LSE:BXP
Total Premiums Earned is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Beximco Pharmaceuticals (LSE:BXP) Overvalued in 2026?

Based on GuruFocus' analysis, Beximco Pharmaceuticals stock appears to be overvalued. The current stock price of £0.63 is trading 27.6% above its estimated GF Value™ of £0.49. GuruFocus considers Beximco Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for LSE:BXP:

  • Total Premiums Earned:
  • GF Value™: £0.49 vs. price of £0.63 (27.6% above fair value)
  • GF Score™: 55/100 with 6 warning signs

No single metric tells the full story. See the LSE:BXP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beximco Pharmaceuticals Business Description

Address 19 Dhanmondi, Road No. 7, Dhaka, BGD, 1205
Beximco Pharmaceuticals PLC is a Bangladesh-based manufacturer and marketer of generic pharmaceutical formulations, active pharmaceutical ingredients, intravenous fluids, and therapeutic nutrition products. Its portfolio spans antibiotics, cardiovascular, respiratory, musculoskeletal, and central nervous system drugs, hormones, steroids, antihistamines, oral contraceptives, vitamins and mineral supplements, and women's health products. The company sells branded generics in Bangladesh, where it maintains a leading position and derives the majority of its revenue, and exports to numerous countries across Asia, Africa, the Middle East, Europe, and Latin America, including regulated markets such as the United States and Australia. It also supplies contract manufacturing and API services to international partners. Revenue comes from domestic and export sales of finished dosage forms, intravenous fluids, and APIs, supported by its own manufacturing facilities near Dhaka.
55GF Score

Get the complete analysis for LSE:BXP

Total Premiums Earned is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.63
Price
£0.49
GF Value